Management Change/Compensation (Form 8-K)

Separation Agreement

As previously announced, on April 10, 2026, the board of directors (the "Board") of Tango Therapeutics, Inc. (the "Company") determined that Daniella Beckman will no longer serve as the Company's Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.

In connection with Ms. Beckman's separation, on May 7, 2026, the Company and Ms. Beckman entered into a Separation Agreement and Release (the "Separation Agreement"). Pursuant to the terms of the Separation Agreement and to the terms of that certain Employment Agreement by and between the Company and Ms. Beckman, the Company has agreed to provide certain benefits to Ms. Beckman, including the following: (i) twelve months of severance pay at Ms. Beckman's current base salary, paid out in substantially equal installments over 12 months and (ii) reimbursement for any monthly COBRA premium payments for up to 12 months. The Company also agreed to accelerate the vesting of such number of Ms. Beckman's outstanding option and restricted stock unit awards that would have otherwise vested had Ms. Beckman remained in continuation of her service with the Company for an additional twenty-four months following May 1, 2026, Ms. Beckman's last day of employment with the Company. In addition, the Company agreed to extend the post-termination exercise period for any of Ms. Beckman's vested stock options as of the date of the Separation Agreement through August 31, 2026.

In order to receive the foregoing benefits, Ms. Beckman executed a general release in favor of the Company.

The foregoing description of the terms and conditions of the Separation Agreement does not purport to be complete and is qualified in its entirety by the Separation Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.